Walk into any pharmacy, department store, or open any beauty brand's website, and the language is confident and specific. "Clinically proven to reduce wrinkles by 47% in 4 weeks." "Dermatologically tested." "Microbiome-friendly." "Gynaecologically approved." "SPF 50+ broad spectrum protection."
These claims are not decorative. They are commercial commitments — to consumers who are making purchase decisions based on them, to retailers who are listing products based on them, and increasingly, to regulators who are scrutinizing them with a rigour that the cosmeceutical industry has not historically faced.
The question that separates the cosmeceutical brands that will define the next decade from those that will struggle to maintain shelf space is not whether to generate clinical evidence. The direction of travel — regulatory, commercial, and consumer — makes that answer clear. The question is how to generate evidence that is rigorous enough to be defensible, specific enough to be meaningful, and efficiently enough to support the product development timelines that beauty and personal care brands operate on.
Why Cosmeceutical Claims Are Under Greater Scrutiny Than Ever Before
The cosmeceutical category occupies a peculiar regulatory position. Products that make cosmetic claims — statements about appearance rather than physiological function — are regulated as cosmetics in most major markets, subject to safety requirements but not to the pre-market efficacy demonstration required for pharmaceutical products. But consumer expectations, retailer listing requirements, and the advertising standards that govern how claims are communicated have all moved significantly toward demanding substantiation that resembles pharmaceutical-grade clinical evidence.
In the European Union, the EU Cosmetics Regulation (EC 1223/2009) requires that cosmetic claims be substantiated and that substantiation documentation be maintained in the product information file and available for regulatory inspection. The European Commission's Common Criteria for claims require that claims be truthful, evidenced, honest, fair, and not misleading — criteria that advertising standards bodies across the EU are applying with increasing rigour.
In India, the Bureau of Indian Standards and CDSCO's evolving regulatory framework for cosmetics and personal care products are moving in the same direction — toward expectations that claims made on packaging and in advertising are backed by documented evidence that can be produced on request. The Advertising Standards Council of India has been increasingly active in reviewing cosmetic advertising claims, and brands that cannot produce the evidence behind their claims face both regulatory and reputational risk.
For intimate care and vaginal hygiene products specifically, the regulatory environment is more demanding still. Claims about vaginal pH compatibility, microbiome preservation, and gynaecological safety are evaluated against a scientific standard that requires properly conducted clinical studies — not laboratory bench tests or general ingredient safety data.
And for international brands — those selling into the US, EU, UK, and Australian markets simultaneously — the cumulative claim substantiation requirements across jurisdictions create a documentation burden that makes structured clinical evidence generation not a luxury but an operational necessity.
The Three Categories of Cosmeceutical Evidence
The clinical evidence that cosmeceutical brands need falls into three distinct categories, each serving a different purpose and requiring a different study design approach.
Safety Evidence: The Non-Negotiable Foundation
Safety is not a differentiating claim. It is a prerequisite for market entry. But generating the right safety evidence — in a form that satisfies both regulatory requirements and retail buyer qualification processes — requires more than assuming that ingredients with established safety profiles in other contexts are automatically safe in a new formulation.
The Human Repeat Insult Patch Test (HRIPT) is the gold standard for skin sensitization assessment and the foundational study behind "hypoallergenic," "dermatologically tested," and "suitable for sensitive skin" claims. Conducted under dermatologist supervision across a panel of subjects through induction and challenge phases, HRIPT provides a systematic assessment of the product's sensitization potential that cannot be replaced by ingredient-level safety data alone. The formulation as a whole — not its constituent ingredients in isolation — is what consumers apply to their skin, and it is the formulation as a whole that HRIPT evaluates.
For products used near or on the ocular area — eye creams, mascaras, eyeliners, and increasingly the broad category of multipurpose skincare — ophthalmologist-supervised eye area tolerance testing is required to substantiate "ophthalmologically tested" claims. The absence of this testing does not mean a product is unsafe — but it means any claim of ophthalmological testing cannot be made, and many retail buyers and regulatory authorities will ask for it.
For intimate care products, safety evidence requirements are more extensive. Gynaecologist-supervised clinical evaluation of vaginal mucosa tolerance, osmolality measurement within the WHO-recommended range of 200 to 380 mOsm/kg, and vaginal pH compatibility assessment are all required to substantiate the safety claims that intimate care products routinely make. A wash that is "pH-balanced for intimate use" without osmolality data that demonstrates vaginal compatibility is making a claim that half its substantiation is missing.
Efficacy Evidence: The Commercial Differentiator
Efficacy evidence is where clinical research becomes a competitive asset rather than a compliance cost. In markets where multiple brands make similar formulations with similar ingredients, the brand that can demonstrate clinical efficacy with specificity and statistical rigour occupies a different commercial position from the one that relies on ingredient marketing alone.
Anti-ageing claims — wrinkle reduction, skin firmness, elasticity improvement — require objective, instrument-based measurements that cannot be replicated by consumer perception surveys or before-and-after photographs. Cutometer measurements of skin biomechanical properties, Visioscan assessments of skin surface texture, and TEWL measurement of skin barrier function provide the objective evidence that gives anti-ageing claims credibility with dermatologists, with discerning consumers, and with the advertising standards bodies that evaluate whether claims are misleading.
Moisturisation and hydration claims require Corneometer-based skin hydration assessment at defined timepoints following product application — demonstrating both the immediate effect and the durability of hydration over the claim period. A product that claims "24-hour moisturisation" requires data at 24 hours, not just at 30 minutes post-application.
Skin brightening and whitening claims require colorimetric assessment using Mexameter or Chromameter instruments that provide objective, reproducible measurements of skin tone and brightness — not subjective consumer ratings that vary with lighting conditions and individual perception biases.
Anti-friction and anti-chafing efficacy — an increasingly important claim category as brands develop products for active consumers and plus-size populations experiencing friction-related skin conditions — requires in vivo testing under real-use conditions that simulate the friction exposure the product is designed to protect against.
For hair and scalp products, clinical assessment of anti-dandruff efficacy, sebum control, and hair loss reduction requires standardized methodologies that produce data meeting the evidentiary standard that anti-dandruff drug claims in regulated markets require.
Microbiome Evidence: The Emerging Frontier
The skin and vaginal microbiome have become one of the most commercially significant areas of cosmeceutical science in the past five years — and one of the most scientifically demanding to substantiate properly.
"Microbiome-friendly" is now one of the most common claims in skin care and intimate care product marketing. It is also one of the most poorly substantiated, because the laboratory tests that many brands rely upon — in vitro assessments of individual bacterial species under artificial conditions — do not provide meaningful evidence about what happens to the actual microbiome of an actual person using the product in real-life conditions.
Proper microbiome substantiation requires clinical studies using molecular methods — 16S rRNA sequencing for skin microbiome diversity assessment, quantitative PCR for specific species quantification in vaginal samples — conducted on human subjects using the finished product under conditions representative of actual use. For intimate care products making Lactobacillus preservation claims, qPCR-based quantification of vaginal Lactobacillus species before and after product use, in a clinically supervised study with adequate sample sizes and appropriate statistical analysis, is what genuine microbiome evidence looks like.
This is a higher bar than many brands currently meet — and it is precisely that gap between the claim and the evidence behind it that creates the opportunity for brands serious about microbiome science to differentiate themselves from those trading on the term without substantiation.
The Indian Advantage for Cosmeceutical Clinical Testing
India offers cosmeceutical brands — both domestic and international — a combination of scientific capability, diverse study populations, cost efficiency, and regulatory expertise that is genuinely difficult to replicate in other markets.
India's diverse population — encompassing Fitzpatrick skin types III through VI, a range of climatic conditions from humid tropical to arid and temperate, and significant variation in microbiome profiles across geographic and demographic groups — provides study populations that generate clinically meaningful data across a broader skin type range than studies conducted exclusively in fair-skinned Western populations. For brands targeting Asian, South Asian, or global markets, efficacy data generated in India's population is both more representative and more commercially relevant than data generated in populations that do not reflect the brand's target consumers.
The dermatologist, ophthalmologist, and gynaecologist networks required for supervised cosmeceutical clinical testing are well-established in India's major urban centers and increasingly accessible in secondary cities — providing the clinical infrastructure for studies that require specialist physician oversight without the access challenges and physician fee structures that affect cosmeceutical testing in the US and EU.
And the cost structure — cosmeceutical clinical studies in India typically cost 40 to 60 percent less than equivalent studies in Europe or the United States — changes the financial calculus for evidence generation in ways that make comprehensive testing programs viable for brands that could not afford equivalent programs in Western markets.
For international brands, the critical question is regulatory acceptability: will clinical evidence generated in India be accepted by EU, US, UK, and Australian regulatory bodies and retail buyers? The answer, for studies designed and conducted to appropriate international methodological standards and reported in formats consistent with EU Cosmetics Regulation requirements and ICH E3 reporting guidelines, is yes. The study design, the validated instrumentation, the statistical methodology, and the quality of the clinical study report — not the geographic location of the study — are what determine regulatory and commercial acceptability.
Claim Design: Where Evidence Strategy Begins
The most common and most costly mistake in cosmeceutical clinical evidence generation is designing the study before designing the claim — conducting a clinical study and then working backward to determine what claims the data supports.
The correct sequence is the reverse. The claim — precisely worded, specific in its scope, and aligned with the regulatory requirements of every market in which it will be made — is the starting point. From the claim, the study design follows: what endpoints need to be measured, in what population, over what time period, with what instrument, at what statistical power. And from the study design, the evidence package follows: the clinical study report, the marketing claim substantiation document, and the regulatory dossier documentation.
This forward-designed approach — from claim to study to evidence — produces data that is specific enough to defend, general enough to use across markets, and efficient enough to generate without redundant studies for different regulatory jurisdictions.
At Genelife Clinical Research, our cosmeceutical clinical testing programs begin with claim design and regulatory strategy — working with brands to define the claims they want to make, the markets they want to make them in, and the evidence requirements of each — before a single study design decision is made. This approach produces evidence that is commercially useful from the first day the study report is delivered, not after months of additional work to translate raw data into usable claim documentation.
Conclusion
The cosmeceutical industry's claim environment is changing. Regulatory agencies, advertising standards bodies, and retail buyers in every major market are demanding evidence that is more rigorous, more specific, and more systematically documented than the industry has historically required. Brands that build their clinical evidence base now — with properly designed safety studies, instrument-based efficacy assessments, and genuinely scientific microbiome substantiation — are building a competitive position that ingredient marketing alone cannot provide.
India offers the scientific infrastructure, the population diversity, the specialist clinical networks, and the cost efficiency to make comprehensive cosmeceutical clinical evidence generation not just feasible, but strategically compelling. And a CRO partner who understands both the science and the commercial objectives — who designs studies from the claim backward rather than from the protocol forward — is the difference between evidence that sits in a filing cabinet and evidence that drives commercial decisions.
Genelife Clinical Research provides comprehensive cosmeceutical clinical testing services — from HRIPT and SPF testing through microbiome studies, gynaecology assessment, and claim substantiation dossier preparation — for domestic and international personal care brands. To learn more, visit genelifecr.com/strategies/cosmeceutical.
